What are the criteria for determining resectability in gastric neuroendocrine carcinoma?

Resectability Criteria for Gastric Neuroendocrine Carcinoma

Surgery should be offered to patients who are fit and have limited disease—specifically, disease confined to the primary tumor and regional lymph nodes without distant metastases. 1

Core Resectability Criteria

The fundamental principle for determining resectability in gastric neuroendocrine carcinoma (NEC) follows the same framework as other gastroenteropancreatic neuroendocrine tumors:

Resectable Disease Includes:

• Localized disease: Primary tumor confined to the stomach with or without regional lymph node involvement (N0-N3) 1
• No distant metastases (M0 disease) 1
• Adequate patient performance status: Patient must be medically fit to tolerate surgery 1
• Absence of other life-limiting comorbidities 2

Potentially Resectable Disease:

Surgery should be considered in patients with liver metastases and potentially resectable disease 1. This represents a critical nuance—unlike many other malignancies, selected patients with hepatic metastases may still benefit from surgical resection if:

• Near-complete cytoreduction can be achieved (typically >90% tumor removal) 2
• The patient has adequate performance status 2
• Liver metastases are technically resectable 1

Staging Requirements Before Determining Resectability

The extent of the tumor, its metastases, and secretory profile should be determined as far as possible before planning treatment 1. This requires:

Imaging Workup:

• CT scan of thorax, abdomen, and pelvis 3
• Endoscopic ultrasound (EUS) to determine T stage and extent 3
• Somatostatin receptor scintigraphy (SSRS) as the most sensitive modality for assessing metastases 1
• Laparoscopy with or without peritoneal washings in all potentially resectable cases to exclude occult metastatic disease 3
• Consider MRI, DSA, or venous sampling as part of multimodality approach 1

Biochemical Assessment:

• Chromogranin A (CgA) 1
• 5-HIAA if carcinoid syndrome suspected 1
• Specific hormone markers based on clinical presentation 1

Surgical Approach for Resectable Disease

For gastric NECs deemed resectable, the surgical approach should mirror that of gastric adenocarcinoma:

• Adequate regional lymph node resection including all palpable disease where feasible 2
• Negative surgical margins (R0 resection) 2
• Thorough exploration for synchronous primary tumors (15-30% incidence in gastrointestinal carcinoids) 2

Contraindications to Resection

Unresectable disease includes:

• Widely metastatic disease 2
• High surgical risk patients 2
• Other life-limiting comorbidities 2
• Extensive hepatic involvement where near-complete cytoreduction cannot be achieved 2

Critical Prognostic Factors Informing Resectability Decisions

Recent research provides important context for surgical decision-making in gastric NECs:

Tumor size and N stage are independent prognostic factors 4. Specifically:

• Larger tumors have worse outcomes 4, 5
• Lymph node metastasis significantly impacts prognosis 4, 6
• T3-T4 stage and lymph node metastasis are independent risk factors for distant recurrence 6

Ki-67 labeling index and mitotic index are independent prognostic factors, with higher proliferative indices associated with worse survival 4, 5. However, these factors inform prognosis rather than resectability per se.

Special Considerations

Palliative Resection:

Even in the setting of unresectable metastases, palliative resection of the primary tumor may be indicated if the patient develops symptoms such as:

• Obstruction
• Bleeding
• Perforation
• Hormone hypersecretion symptoms 2

Cytoreductive Surgery:

Patients with symptomatic recurrence from local effects or hormone hypersecretion can be effectively palliated by subtotal resection (typically >90% tumor removal) 2. However, planned cytoreductive incomplete (R2) resection in asymptomatic or nonfunctional disease remains controversial 2.

Recurrent Disease:

Resection of recurrent locoregional disease, isolated distant metastases, or previously unresectable tumor that has regressed should be considered for selected patients with adequate performance status 2.

Common Pitfalls

1. Failing to perform laparoscopy: Laparoscopy is recommended in all potentially resectable cases to exclude peritoneal metastases that may not be visible on CT 3

2. Underestimating the role of surgery in oligometastatic disease: Unlike many malignancies, selected patients with limited hepatic metastases may benefit from aggressive surgical cytoreduction 1

3. Not considering prophylactic cholecystectomy: When abdominal surgery is undertaken and long-term somatostatin analogue therapy is anticipated, cholecystectomy should be considered due to increased risk of biliary symptoms 2, 1, 2, 1

4. Confusing gastric NETs with gastric NECs: The evidence provided primarily addresses well-differentiated NETs. Gastric NECs (poorly differentiated, high-grade) are more aggressive and require more aggressive surgical approaches similar to gastric adenocarcinoma 7, 8